Time (days on ventilator) | Non-VAP patients | Time (days relative to VAP) | VAP patients | ||||
---|---|---|---|---|---|---|---|
TATc levels in plasma (ng/ml) | PAA levels in plasma (IU/ml) | N | TATc levels in plasma (ng/ml) | PAA levels in plasma (IU/ml) | N | ||
Data are presented as median (interquartile range). | |||||||
TATc = thrombin-antithrombin complexes; PAA = plasminogen activator activity; N = number of patients at indicated time point. | |||||||
*Change in time. | |||||||
†Compared with non-VAP patients. | |||||||
No data are presented when <3 samples could be analysed. | |||||||
Fibrinolysis in patients with VAP. | |||||||
0 | 5.3 (3.8–6.8) | 100 (100–100) | 19 | −6 | 6.2 (4.8–7.2) | 100 (100–108) | 9 |
2 | 5.9 (4.1–6.9) | 102 (102–129) | 19 | −4 | 6.9 (6.5–7.1) | 102 (100–110) | 9 |
4 | 6.2 (4.5–7.1) | 113 (103–123) | 19 | −2 | 7.9 (7.7–9.1) | 99 (86–121) | 9 |
6 | 6.0 (4.5–6.9) | 106 (100–117) | 10 | 0 | 9.7 (8.3–10.5) | 97 (90–127) | 9 |
8 | 5.4 (4.6–8.9) | 121 (99–123) | 7 | 2 | 9.4 (7.6–11.6) | 92 (81–112) | 9 |
10 | 5.0 (4.8–5.7) | 125 (117–132) | 5 | 4 | 10.9 (7.2–11.5) | 90 (87–100) | 9 |
12 | 5.1 (4.6–5.5) | 129 (111–130) | 3 | 6 | 11.4 (9.1–12.4) | 93 (86–111) | 9 |
14 | 5.3 (5.0–5.4) | 118 (107–131) | 3 | 8 | 10.7 (8.6–12.3) | 88 (82–105) | 5 |
16 | 5.3 (5.3–5.6) | 121 (110–130) | 3 | 10 | 12.9 (9.2–14.4) | 96 (82–120) | 3 |
p = 0.34* | p = 0.0003* | p = 0.003* | p = 0.07* | ||||
p = 0.02† | p<0.0001† |